Paul Heidenreich, MD
Academic Appointments
- Professor - Med Center Line, Medicine - Cardiovascular Medicine
- Professor - Med Center Line (By courtesy), Health Research & Policy
Key Documents
Contact Information
- Academic Offices
Personal Information Email
Professional Overview
Honors and Awards
- Clinical Divisional Teaching Award, Stanford University, Department of Medicine (2008)
- E. William Hancock Cardiovascular Medicine Teaching Award, Stanford University, Department of Medicine, Division of Cardiology (2001)
- Clinical Divisional Teaching Award, Stanford University, Department of Medicine (2001)
Professional Education
| Medical Education: | University of Chicago - Registrar IL (6/1/88) |
| Internship: | UCLA - School of Medicine CA (6/90) |
| Residency: | *UCSF Dean's Office Postdoctoral Education CA (6/92) |
| Fellowship: | *UCSF Dean's Office CA (6/95) |
| MD: | University of Chicago, Medicine (1988) |
| MS: | Stanford University, Health Services Research (1998) |
Scientific Focus
Current Research Interests
My research interests include
1) The cost-effectiveness of new cardiovascular technologies.
Example: tests to screen asymptomatic patients for left ventricular systolic dysfunction.
2) Interventions to improve the quality of care of patients with heart disease. Examples: include clinical reminders and home monitoring.
3) Outcomes research using existing clinical and administrative datasets.
4) Use of echocardiography to predict prognosis (e.g. diastolic dysfunction).
Publications
- Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA. 2013; (19): 2025-34
- Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association. Circ Heart Fail. 2013
- Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol. 2013; (13): 1440-6
- Measuring the quality of echocardiography using the predictive value of the left ventricular ejection fraction. J Am Soc Echocardiogr. 2013; (3): 237-42
- Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013; (1): 55-62
- Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012; (20): 2097-107
Help